Physician profile
Megan E Slade
NPI 1811244593
$1,144.90
in general payments reported to CMS, 2019-2025
10 companies · $43.86 in 2025
The $43.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $467 · 2022: $214 · 2023: $321 · 2024: $99.34 · 2025: $43.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $480.36 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $143.52 | 2021-2025 | Abilify Asimtufii |
| Astellas Pharma Global Development | $129.60 | 2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $91.40 | 2021-2024 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $70.36 | 2021-2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $67.00 | 2022-2024 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $65.93 | 2021-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $45.17 | 2021-2022 | |
| Indivior INC. | $38.31 | 2023 | Perseris |
| Vanda Pharmaceuticals INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Slade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.